Novavax earned a $125 million milestone from Sanofi after starting a Phase III combination COVID-flu vaccine trial in Europe. Sanofi also plans a U.S. trial, and Novavax is eligible to earn $225 million on a first U.S. sale.
NVAX · Novavax Inc
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
Novavax reported revenue of $68.3 million and a net loss of $31.4 million, or $0.19 per share, for the three months ended September 30, 2026, versus a $202.4 million loss, or $1.25 per share, in 2025. R&D expenses fell to $52.4 million from $98.3 million.
Novavax raised its 2026 adjusted total revenue guidance to $385 - $415 million after earning a $125 million milestone from Sanofi, while third-quarter revenue was $68 million and net loss was $31 million.
Sanofi dosed the fifth patient on October 28, 2026 in its Phase 3 influenza-COVID-19 combination vaccine trial in the European Union, triggering a $125 million milestone payment to Novavax expected by the first quarter of 2027.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q2 FY26 earnings call · Aug 6, 2026TL;DR. Novavax raised its 2026 adjusted total revenue framework to $235 million to $275 million and improved combined GAAP R&D and SG&A guidance by $10 million at midpoint. Second-quarter total revenue fell 76% to $57 million, and the company reported a net loss of $53 million.
- + Raised full-year 2026 adjusted total revenue framework to $235 million to $275 million.
- + Product sales rose 76% year over year on higher Matrix-M adjuvant demand and sales to license partners.
- + Sanofi's expected Phase 3 CIC trial initiation in the U.S. or EU would trigger a $125 million milestone to Novavax.
- + Sanofi manufacturing technology transfer, expected mid-2027, would trigger a $75 million milestone to Novavax.
- + Combined GAAP R&D and SG&A expense guidance improved by $10 million at midpoint.
- + Non-GAAP R&D expenses, net of partner reimbursement, fell 34% year over year to $48 million.
- − Total revenue fell 76% year over year to $57 million in the second quarter.
- − Net loss of $53 million in the second quarter, compared with net income of $107 million a year earlier.
- − Sanofi revenue fell 82% year over year, to 36 from 199 ($ in millions).
- − Licensing, royalties and other revenue fell 83% year over year, to 38 from 229 ($ in millions).
- − Cash declined to $724 million at June 30, 2026 from $751 million at December 31, 2025.
- − Possible non-cash fixed asset write-off of up to $35 million in 2027.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Cash, cash equivalents, marketable securities and restricted cash (Cash) | $627M | as of September 30, 2026 | — |
| Non-GAAP Combined R&D and SG&A Expenses non-GAAP | $243.6M | Nine Months Ended September 30, 2026 | — |
|
|
|||
| Non-GAAP R&D Expenses non-GAAP | $164.5M | Nine Months Ended September 30, 2026 | — |
|
|
|||
| R&D expenses reimbursed by partners | $4M | the third quarter of 2026 | — |
|
|
|||
| Non-GAAP R&D expenses, net of partner reimbursement non-GAAP | $48M | Q2 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
NVAX
this stock
Novavax Inc
|
$1.31B | +18.5% | +64.7% | — | 28.1% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$136.01B | +18.3% | +46.2% | 34.5 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$97.81B | +22.5% | +20.8% | 20.9 | 2.1% |
|
MRNA
Moderna, Inc.
|
$79.63B | +567.3% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$63.15B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 17, 2026
- This year
- 19
Novavax earned a $125 million milestone from Sanofi after starting a Phase III combination COVID-flu vaccine trial in Europe. Sanofi also plans a U.S. trial, and Novavax is eligible to earn $225 million on a first U.S. sale.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| NVAX | -20.2% | -27.7% | -27.4% | -21.0% | +18.5% |
| SPY | -3.9% | -5.6% | -3.5% | -3.4% | +7.1% |
| vs SPY | -16.3% | -22.2% | -24.0% | -17.7% | +11.4% |